当天机构净买入前三的股票分别是景旺电子、德科立、北方长龙，净买入金额分别是2.5亿元、1.38亿 元、1.16亿元。 | 祥鑫科技 | 10.01% | -1011.37 | | --- | --- | --- | | 科净源 | 20.02% | -1023.01 | | 拓山重工 | 4.40% | -1099.08 | | 中化国际 | 10.10% | -1997.67 | | 方邦股份 | 20.00% | -2460.92 | | 恒宝股份 | 4.63% | -5590.73 | | 和泰机电 | -2.12% | -5658.30 | | 爱婴室 | 2.62% | -8813.31 | | 博云新材 | -6.15% | -2131.81 | | 上海电影 | -7.05% | -2581.69 | | 昭衍新药 | 9.94% | -2830.30 | 当天机构净卖出前三的股票分别是昭衍新药、上海电影、博云新材，净流出金额分别是2830万元、2582 万元、2132万元。 当天机构净买入前三的股票分别是景旺电子、德科立、北方长龙，净买入金额分别是2.5亿元、1.38亿 元、1.16亿元。 ...

经公司自查并书面征询公司控股股东及实际控制人，截至本公告披露日，公司及公司控股股东、实际控 制人确认不存在应披露而未披露的重大信息。 昭衍新药(06127)公布，公司A股股票于 2025 年 7 月 25 日、7 月 28 日和 7 月 29 日连续 3 个交易日内日 收盘价格涨幅偏离值累计超过 20%。根据《上海证券交易所交易规则》的有关规定，属于股票交易异 常波动情形。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：603127 证券简称：昭衍新药 公告编号：2025-028 股票交易异常波动公告 北京昭衍新药研究中心股份有限公司 经公司自查，并书面征询控股股东及实际控制人，截至本公告披露日，不存 在影响公司股票交易价格异常波动的重大事项，不存在涉及公司应披露而未披露 的重大信息，包括但不限于重大资产重组、发行股份、上市公司收购、债务重组、 资产剥离和资产注入等重大事项。 针对公司股票交易异常波动，公司对有关事项进行了核查，现将有关情况说 明如下： 北京昭衍新药研究中心股份有限公司（以下简称"公司"）股票于2025 年7月25日、7月28日和7月29日连续3个交易日内日收盘价格涨幅偏离值 累计超过20%。根据《上海证券交易所交易规则》的有关规定，属于股 票交易异常波动情形。 经公司自查并书面征询公司控股股东及实际控制人，截至本公告披露日， 公司及公司控股股东、实际控制人确认不存在应披露而未披露的重大信 息。 （一）生产经营情况 经自查，公司目前生产经营活动正常 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年7月29日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 先 生、陽 ...

经济观察网 昭衍新药（603127）公告，公司股票于2025年7月25日、7月28日和7月29日连续3个交易日 内日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动情形。经公司自查并书面征询公司控股 股东及实际控制人，确认不存在应披露而未披露的重大信息。公司生产经营活动正常，内、外部经营环 境未发生重大变化，不存在影响公司股票交易价格异常波动的应披露而未披露的重大信息。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002173 | 创新医疗 | 14.25 | -2.40% | 30.64万 | 4.38亿 | | 600568 | ST中珠 | 1.71 | -1.16% | 25.07万 | 4270.89万 | | 301060 | 兰卫医学 | 10.88 | -0.91% | 15.48万 | 1.68 Z | | 002622 | 皓宸医疗 | 3.08 | -0.65% | 19.90万 | 6122.15万 | | 835670 | 数字人 | 15.01 | -0.27% | 2.46万 | 3694.46万 | | 002172 | 澳洋健康 | 4.04 | -0.25% | 76.58万 | 3.11亿 | | 301293 | 三博脑科 | 48.88 | -0.10% | 6.96万 | 3.37亿 | | 300143 | 宮康生命 | 10.13 | 0.10% | 9.68万 | 9742.32万 | | 002044 | ...

Group 1 - The Hong Kong pharmaceutical outsourcing sector has strengthened, with companies such as Kanglong Chemical (03759.HK) and WuXi AppTec (02359.HK) rising over 3% [1] - Other companies like Zhaoyan New Drug (06127.HK) and Tiger Med (03347.HK) also experienced gains [1]

Company Overview - Zhao Yan New Drug closed at 32.0 yuan, up 7.02%, with a rolling PE ratio of 61.91, the lowest in 488 days, and a total market value of 23.983 billion yuan [1] - The company specializes in non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1] Financial Performance - For Q1 2025, the company reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit was 41.1195 million yuan, a year-on-year increase of 115.11%, with a gross margin of 28.61% [1] Shareholder Information - As of September 30, 2020, the number of shareholders was 17,882, a decrease of 783 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical services industry is 48.04, with a median of 58.89, placing Zhao Yan New Drug at 30th in the industry ranking [1][2] - The static PE ratio for Zhao Yan New Drug is 32.77, with a price-to-book ratio of 2.96 [2]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Group 1: Market Overview - The Hang Seng Index fell by 1.11%, down 284 points, closing at 25,383 points, while the Hang Seng Tech Index dropped by 1.69% [1] - The early trading volume in Hong Kong stocks reached 151 billion HKD [1] Group 2: Medical Sector - Medical device stocks rose in early trading, with the national drug procurement policy indicating a move away from internal competition, leading institutions to view this as a turning point for the industry [1] - Aikang Medical (01789) increased by 7.93%, and Weigao Group (01066) rose by 4.37% [1] - Yongsheng Medical (01612) saw a surge of over 27% following a profit warning, with sales orders increasing and expected mid-term net profit growth exceeding 50% year-on-year [2] - CRO concept stocks continued to rise, with Citigroup noting that the CXO sector is gaining market attention ahead of earnings season [2] - Kanglong Chemical (300759) (03759) rose by 8.4%, while Zhaoyan New Drug (603127) (06127) increased by 5.7%, and WuXi Biologics (02269) rose by 4.5% [2] Group 3: Consumer Sector - Nongfu Spring (09633) increased by over 3.56%, reaching a three-and-a-half-year high, with institutions expecting the company's first-half revenue growth to exceed market expectations [3] Group 4: Other Notable Stocks - Jihong Co., Ltd. (002803) (02603) rose by 16%, with two main business segments performing well, and expected first-half net profit growth of up to 65% [4] - China Merchants Port (01199) increased by over 4%, following reports that China Merchants Group plans to acquire assets from Cheung Kong Ports [5] - Guichuang Tongqiao (02190) rose by 2.6%, with expected mid-term net profit growth of 66.9%, as the company embraces procurement and actively expands overseas [6] Group 5: Lithium and Duty-Free Sector - News of supply disruptions in the lithium market led to Tianqi Lithium (002466) (09696) rising by 3.6% [7] - China Duty Free Group (601888) (01880) fell by over 6%, with pending details on Hainan's duty-free policies, and institutions noting that the closure operations have a dual impact on offshore duty-free business [7] Group 6: Technology Sector - Qianxun Technology (01640) fell by over 3%, having retreated 23% from its previous high, with recent comments from Yu Weiwen emphasizing the need to avoid excessive speculation on stablecoins [8]